RU2014150265A - Оптимальный дозовый режим антитела против nogo-a в лечении бокового амиотрофического склероза - Google Patents
Оптимальный дозовый режим антитела против nogo-a в лечении бокового амиотрофического склероза Download PDFInfo
- Publication number
- RU2014150265A RU2014150265A RU2014150265A RU2014150265A RU2014150265A RU 2014150265 A RU2014150265 A RU 2014150265A RU 2014150265 A RU2014150265 A RU 2014150265A RU 2014150265 A RU2014150265 A RU 2014150265A RU 2014150265 A RU2014150265 A RU 2014150265A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- nogo
- days
- colocalization
- maintained
- Prior art date
Links
- 208000034189 Sclerosis Diseases 0.000 title 1
- 230000008045 co-localization Effects 0.000 claims abstract 14
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 7
- 239000012634 fragment Substances 0.000 claims abstract 4
- 102000010410 Nogo Proteins Human genes 0.000 claims abstract 2
- 108010077641 Nogo Proteins Proteins 0.000 claims abstract 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract 2
- 210000000170 cell membrane Anatomy 0.000 claims abstract 2
- 230000002008 hemorrhagic effect Effects 0.000 claims abstract 2
- 230000000302 ischemic effect Effects 0.000 claims abstract 2
- 208000020431 spinal cord injury Diseases 0.000 claims abstract 2
- 230000009529 traumatic brain injury Effects 0.000 claims abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- FASDKYOPVNHBLU-SSDOTTSWSA-N dexpramipexole Chemical compound C1[C@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-SSDOTTSWSA-N 0.000 claims 1
- 229950004920 dexpramipexole Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668134P | 2012-07-05 | 2012-07-05 | |
| US61/668,134 | 2012-07-05 | ||
| PCT/EP2013/064063 WO2014006105A1 (en) | 2012-07-05 | 2013-07-03 | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014150265A true RU2014150265A (ru) | 2016-08-27 |
Family
ID=48741180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014150265A RU2014150265A (ru) | 2012-07-05 | 2013-07-03 | Оптимальный дозовый режим антитела против nogo-a в лечении бокового амиотрофического склероза |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102279751B1 (ko) * | 2019-06-28 | 2021-07-21 | 경북대학교 산학협력단 | 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법 |
| KR102409771B1 (ko) * | 2020-06-17 | 2022-06-16 | 경북대학교 산학협력단 | Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| DE10336350B4 (de) | 2003-08-08 | 2007-10-31 | Westfalia Separator Ag | Vollmantel-Schneckenzentrifuge, mit Schälscheibe |
| GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| JP2007537145A (ja) | 2003-12-22 | 2007-12-20 | グラクソ グループ リミテッド | アルツハイマー病の治療のためのｎｏｇｏａ抗体 |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| MX2010004831A (es) | 2007-11-02 | 2010-05-21 | Novartis Ag | Moleculas de enlace de nogo-a mejoradas y uso farmaceutico de las mismas. |
| WO2010004031A2 (en) | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
-
2013
- 2013-07-03 IN IN2952KON2014 patent/IN2014KN02952A/en unknown
- 2013-07-03 AU AU2013285493A patent/AU2013285493A1/en not_active Abandoned
- 2013-07-03 WO PCT/EP2013/064063 patent/WO2014006105A1/en active Application Filing
- 2013-07-03 JP JP2015519214A patent/JP2015521992A/ja not_active Withdrawn
- 2013-07-03 KR KR20157003097A patent/KR20150036398A/ko not_active Withdrawn
- 2013-07-03 RU RU2014150265A patent/RU2014150265A/ru not_active Application Discontinuation
- 2013-07-03 CN CN201380035806.8A patent/CN104395343A/zh active Pending
- 2013-07-03 BR BR112014032987A patent/BR112014032987A2/pt not_active IP Right Cessation
- 2013-07-03 EP EP13732986.8A patent/EP2870177A1/en not_active Withdrawn
- 2013-07-03 CA CA2876284A patent/CA2876284A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014032987A2 (pt) | 2017-06-27 |
| CN104395343A (zh) | 2015-03-04 |
| WO2014006105A1 (en) | 2014-01-09 |
| AU2013285493A1 (en) | 2015-01-22 |
| JP2015521992A (ja) | 2015-08-03 |
| IN2014KN02952A (enrdf_load_stackoverflow) | 2015-05-08 |
| EP2870177A1 (en) | 2015-05-13 |
| CA2876284A1 (en) | 2014-01-09 |
| KR20150036398A (ko) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
| EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| PH12015500507A1 (en) | Humanized antibodies to amyloid beta | |
| PH12014502584A1 (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| MY164579A (en) | Safe and functional humanized antibodies | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| EA201791993A1 (ru) | Способы лечения протеинопатий | |
| MA33076B1 (fr) | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| WO2009149486A3 (en) | Compounds for treating beta-amyloidoses | |
| EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
| TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
| MX2009012163A (es) | Hetarilanilinas como moduladores para beta-amiloide. | |
| EP3708168A3 (en) | Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia | |
| EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
| PH12021550859A1 (en) | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING a-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | |
| JP2016501219A5 (enrdf_load_stackoverflow) | ||
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| MX2009005351A (es) | Compuestos utiles para tratar trastornos neurodegenerativos. | |
| EA201291040A1 (ru) | Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином | |
| AU2010279892A8 (en) | Humanized anti-amyloid-b oligomer antibody | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171009 |